An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane
@article{Buzdar2002AnOO,
title={An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane},
author={A. Buzdar and J. Robertson and W. Eiermann and J. Nabholtz},
journal={Cancer},
year={2002},
volume={95}
}The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole have shown superior efficacy compared with tamoxifen as first‐line treatments and compared with megestrol acetate as second‐line therapy in postmenopausal women with advanced breast carcinoma. In an open‐label, Phase II trial, it was reported that exemestane showed numerical superiority compared with tamoxifen for objective response and clinical benefit. Because these agents ultimately may be administered… CONTINUE READING
Topics from this paper.
219 Citations
New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma
- Medicine
- Cancer
- 2005
- 31
The adjuvant endocrine treatment revolution: focus on anastrozole
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2006
- 2
Long-term safety of aromatase inhibitors in the treatment of breast cancer
- Medicine
- Therapeutics and clinical risk management
- 2008
- 40
- Highly Influenced
- PDF
Are aromatase inhibitors superior to antiestrogens?
- Medicine
- The Journal of Steroid Biochemistry and Molecular Biology
- 2005
- 28
Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial
- Medicine
- Clinical Cancer Research
- 2004
- 24
Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.
- Medicine
- Breast disease
- 2005
- 17
Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.
- Chemistry, Medicine
- The Journal of clinical endocrinology and metabolism
- 2003
- 57
- PDF
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data
- Medicine
- Journal of surgical oncology
- 2006
- 17
References
SHOWING 1-10 OF 92 REFERENCES
Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 1996
- 79
- Highly Influential
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 1996
- 390
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
- Medicine
- Cancer
- 1998
- 448
Aromatase inhibitors in the treatment and prevention of breast cancer.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2001
- 279
Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
- Medicine
- Cancer research
- 1992
- 152
ARIMIDEX™: A new oral, once-a-day aromatase inhibitor
- Medicine
- The Journal of Steroid Biochemistry and Molecular Biology
- 1995
- 122
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
- Medicine
- Clinical cancer research : an official journal of the American Association for Cancer Research
- 1999
- 89
- PDF